Side-by-side comparison of AI visibility scores, market position, and capabilities
Epigenetic protein engineering company developing liquid biopsy detection tools for the $50B blood test market; backed by Harvard's George Church competing in cancer early detection diagnostics.
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
AI chemical reaction optimization with 95% accuracy for drug discovery synthesis parameters; $4.5M from Khosla Ventures and YC competing to automate pharmaceutical process chemistry development.
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists with AI systems that determine optimal reaction parameters (temperature, solvent, catalyst, concentration) for new chemical synthesis routes, achieving 95% accuracy in suggesting effective conditions for small-scale trials. Founded in 2023 and backed by Khosla Ventures, 468 Capital, 500 Global, and Y Combinator with $4.5 million raised including a $4 million seed round in April 2024, Yoneda Labs brings mathematical category theory foundations (the name references Yoneda's lemma in category theory) to chemistry AI.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.